Things are moving quickly in the race to launch coronavirus vaccines. The next few weeks should be pivotal. In this Motley Fool Live video recorded on Dec. 3, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss the next big catalysts to watch in the COVID vaccine race.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 20, 2020
Corinne Cardina: Keith, looking ahead, what companies will be reporting the next few rounds of data from their trials? What should investors be watching?
Keith Speights: Well, we were mentioning AstraZeneca (AZN 2.31%). They are going to expand their global studies to include that half-dose/full-dose regimen. They didn't have any of that going on in the U.S., for example, so they're starting up a U.S. group that will include that particular regimen. Look for AstraZeneca to announce sometime early next year. I don't know exactly when.
I'm really more interested and seeing what Novavax (NVAX 2.52%) comes out with. They have U.K. late-stage data that they expect to announce in early 2021. Novavax hopes to begin a U.S. study soon.
Also, Johnson & Johnson (JNJ 0.82%). I'm really looking forward to seeing what they report. They should have some data available sometime in early 2021 as well. The thing I'm really excited about Johnson & Johnson is that they have a single-dose vaccine. If their efficacy is high, that could be a real winner. I'm just curious to see what that efficacy level is going to be.
